By using our site you accept the terms of our cookie policy

EnvisionTEC Statement on Patent Infringement Lawsuit Against Formlabs

March 21, 2017


EnvisionTEC, a leading global provider of 3D printing solutions, today issued a statement about its patent infringement lawsuit filed against Formlabs of Somerville, Mass., in the United States District Court for the Central District of California.

In the complaint, EnvisionTEC asserts that Formlabs’ 3D printers infringe upon two patents held by EnvisionTEC.

EnvisionTEC CEO Al Siblani offered the following statement about the company’s decision to pursue this action:

“EnvisionTEC has been inventing, developing, manufacturing and selling 3D printers, materials and other related technologies and services for nearly 15 years. Today, we hold numerous patents around the world covering a variety of our 3D printing products, methods and more. This intellectual property was researched and developed over many years by our innovative team of professionals and is invaluable to our business serving a variety of medical, professional and industrial markets around the world. We are committed to aggressively protecting our intellectual property in accordance with the laws of the countries in which we operate.”

EnvisionTEC’s complaint seeks injunctive relief prohibiting Formlabs from continued infringement as well as remedies in the form of monetary damages for past and current infringement.

About EnvisionTEC

EnvisionTEC is a leading global provider of professional-grade 3D printing solutions. Founded in 2002 with its pioneering commercial DLP printing technology, EnvisionTEC now sells more than 40 printers based on six distinct technologies that build objects from digital design files. The company’s premium 3D printers serve a wide variety of medical, professional and industrial markets, and are valued for precision, surface quality, functionality and speed. EnvisionTEC’s intellectual property includes more than 100 pending and granted patents and 70 proprietary materials. Learn more at

Source: BusinessWire

Contact Us

+44 (0) 203 725 6841